Alana L. Welm

Alana L. Welm, PhD

Languages spoken: English

Academic Information

Departments Primary - Oncological Sciences

Lab

Research Interests

  • Breast Cancer
  • Neoplasm Metastasis
  • Tumor Immunology

Alana Welm, PhD, is Senior Director of Basic Science at the Huntsman Comprehensive Cancer Center, Full Professor in the Department of Oncological Sciences at the University of Utah, and an Investigator at the Huntsman Cancer Institute. Welm's laboratory studies breast cancer metastasis.

Dr. Welm completed her PhD in Cell and Molecular Biology at Baylor College of Medicine in Houston, TX under the supervision of Gretchen Darlington, PhD. She then went on to conduct postdoctoral training in Dr. J. Michael Bishop’s laboratory at the University of California, San Francisco where her work focused on developing new models of breast cancer metastasis. Dr. Welm started her laboratory at the University of Utah’s Huntsman Cancer Institute in 2007, was promoted to Associate Professor with tenure in 2013, and granted Full Professorship in 2019.

The research in Dr. Welm’s laboratory is focused on solving the problem of breast cancer metastasis using in vivo modeling of mouse and human breast cancers. Dr. Welm’s group discovered that the Ron kinase pathway is an important facilitator of breast cancer metastasis through its unique dual function in tumor cells and in resident macrophages. Current areas of research include (1) pre-clinical studies of various Ron inhibitors for treatment and prevention of metastatic breast cancer; (2) pre-clinical and early clinical studies of Ron/Met inhibitors in bone metastatic cancers; (3) discovering molecular mechanisms by which Ron kinases promote metastasis through cell-autonomous and non cell-autonomous pathways; and (4) refining “precision medicine” for metastatic breast cancer using functional assays in patient-derived breast tumor grafts.

Education History

Postdoctoral Fellowship University of California, San Francisco
 Postdoctoral Fellow
Doctoral Training Baylor College of Medicine
 PhD
Undergraduate University of Montana
 BS

Selected Publications

Journal Article

  1. Lei JT, Dobrolecki LE, Huang C, Srinivasan RR, Vasaikar SV, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstam F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B, Lewis MT (2024). Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv. (Read full article)
  2. Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, Soucek K, Navratil J, Svoboda M, Welm AL, Joerger M, Driessen C, Besse L (2024). HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer. (Read full article)
  3. White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi Pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, PDXNet Consortium, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean DA 2nd, Chuang JH (2023). A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res, 84(13), 2060-2072. (Read full article)
  4. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, DAstous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm AL (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO Precis Oncol, 8, e2300724. (Read full article)
  5. Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA (2024). Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. (Read full article)
  6. Geukens T, Maetens M, Hooper JE, Oesterreich S, Lee AV, Miller L, Atkinson JM, Rosenzweig M, Puhalla S, Thorne H, Devereux L, Bowtell D, Loi S, Bacon ER, Ihle K, Song M, Rodriguez-Rodriguez L, Welm AL, Gauchay L, Murali R, Chanda P, Karacay A, Naceur-Lombardelli C, Bridger H, Swanton C, Jamal-Hanjani M, Kollath L, True L, Morrissey C, Chambers M, Chinnaiyan AM, Wilson A, Mehra R, Reichert Z, Carey LA, Perou CM, Kelly E, Maeda D, Goto A, Kulka J, Szkely B, Szasz AM, Tks AM, Van Den Bogaert W, Floris G, Desmedt C (2024). Research autopsy programmes in oncology: shared experience from 14 centres across the world. J Pathol. (Read full article)
  7. Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, Riddell SR, Ghajar CM (2022). Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell, 42(1), 119-134.e12. (Read full article)
  8. Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, Wyczalkowski MA, Mo CK, Liu R, Herndon JM, Davies SR, Liu D, Ding X, Evrard YA, Welm BE, Lum D, Koh MY, Welm AL, Chuang JH, Moscow JA, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields RC, Lim KH, Ma CX, Zhang H, Ding L, Chen F (2023). Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res, 83(24), 4161-4178. (Read full article)
  9. Cannon-Albright LA, Stevens J, Teerlink CC, Facelli JC, Allen-Brady K, Welm AL (2023). A Rare Variant in MDH2 (rs111879470) Is Associated with Predisposition to Recurrent Breast Cancer in an Extended High-Risk Pedigree. Cancers (Basel), 15(24). (Read full article)
  10. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garca-Pedrero J, Caadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R (2023). Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res, 83(19), 3284-3304. (Read full article)
  11. Scherer SD, Zhao L, Butterfield AJ, Yang CH, Cortes-Sanchez E, Guillen KP, Welm BE, Welm AL (2023). Breast cancer PDxO cultures for drug discovery and functional precision oncology. STAR Protoc, 4(3), 102402. (Read full article)
  12. Arnesen S, Polaski JT, Blanchard Z, Osborne KS, Welm AL, OConnell RM, Gertz J (2023). Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs. NAR Cancer, 5(2), zcad027. (Read full article)
  13. Quail DF, Park M, Welm AL, Ekiz HA (2023). Breast Cancer Immunity: It is TIME for the Next Chapter. Cold Spring Harb Perspect Med. (Read full article)
  14. Kidwell CU, Casalini JR, Pradeep S, Scherer SD, Greiner D, Bayik D, Watson DC, Olson GS, Lathia JD, Johnson JS, Rutter J, Welm AL, Zangle TA, Roh-Johnson M (2023). Transferred mitochondria accumulate reactive oxygen species, promoting proliferation. Elife, 12. (Read full article)
  15. Shree Bose, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X (2022). A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell, 40(12), 1448-1453. (Read full article)
  16. Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, Lei JT, Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, Rimawi MF, Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, Malovannaya A, Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, Hilsenbeck SG, Zhang B, Milosavljevic A, Lewis MT (2022). Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience, 26(1), 105799. (Read full article)
  17. Nandi A, Debnath R, Nayak A, To TKJ, Thacker G, Reilly M, Gumber S, Karagounis I, Li N, Lengner CJ, Haldar M, Welm AL, Blanco AM, Thomas C, Chakrabarti R (2021). Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer. Cancer Res, 82(20), 3718-3733. (Read full article)
  18. Petrosyan V, Dobrolecki LE, LaPlante EL, Srinivasan RR, Bailey MH, Welm AL, Welm BE, Lewis MT, Milosavljevic A (2022). Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts. NPJ Breast Cancer, 8(1), 104. (Read full article)
  19. Hoover AR, Liu K, DeVette CI, Krawic JR, Medcalf AD, West CL, Hode T, Lam SSK, Welm AL, Sun XH, Hildebrand WH, Chen WR (2022). Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clin Transl Med, 12(7), e937. (Read full article)
  20. Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T (2022). Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia. (Read full article)
  21. Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H, PDXNet Consortium, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA 2nd, Chuang JH (2022). PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 4(2), zcac014. (Read full article)
  22. Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK (2021). CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep, 38(9), 110448. (Read full article)
  23. Lai SA, Gundlapalli H, Ekiz HA, Jiang A, Fernandez E, Welm AL (2020). Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression. Cancer Discov, 11(12), 3178-3197. (Read full article)
  24. Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, Gregory P, Nottle T, Lang T, Vereker M, Richardson G, Kerr G, Micati D, Jard T, Abud HE, Lee RS, Swarbrick A, Daly RJ (2021). Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Res, 23(1), 82. (Read full article)
  25. Viswanath P, Welm AL (2021). Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse. Cancer Cell, 39(2), 148-150. (Read full article)
  26. Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti R (2021). Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun, 12(1), 432. (Read full article)
  27. Welm BE, Vaklavas C, Welm AL (2021). Toward improved models of human cancer. APL Bioeng, 5(1), 010901. (Read full article)
  28. Riggio AI, Varley KE, Welm AL (2020). The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer, 124(1), 13-26. (Read full article)
  29. Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW (2020). RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer, 124(1), 191-206. (Read full article)
  30. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, OFarrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium (2021). Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet, 53(1), 86-99. (Read full article)
  31. Zarei O, Faham N, Vankayalapati H, Raeppel SL, Welm AL, Hamzeh-Mivehroud M (2020). Ligand-based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase. Mol Inform, 41, e2000181. (Read full article)
  32. Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS (2020). Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res, 22(1), 132. (Read full article)
  33. Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA, Board Members of the Metastasis Research Society (2019). The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis, 36(4), 305-309. (Read full article)
  34. Palomeras S, Diaz-Lagares, Vias G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernndez A, Lum DH, Welm AL, Esteller M, Puig T (2019). Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Res, 21(1), 79. (Read full article)
  35. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627. (Read full article)
  36. Fornetti J, Welm AL, Stewart SA (2018). Understanding the Bone in Cancer Metastasis. J Bone Miner Res, 33(12), 2099-2113. (Read full article)
  37. Faham N, Zhao L, Welm AL (2018). mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ Breast Cancer, 4, 36. (Read full article)
  38. Ekiz HA, Lai SA, Gundlapalli H, Haroun F, Williams MA, Welm AL (2018). Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. Oncoimmunology, 7(9), e1480286. (Read full article)
  39. Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A (2018). EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene, 37(30), 4073-4093. (Read full article)
  40. Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge JS (2018). Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell, 33(6), 985-1003.e7. (Read full article)
  41. DeVette CI, Andreatta M, Bardet W, Cate SJ, Jurtz VI, Jackson KW, Welm AL, Nielsen M, Hildebrand WH (2018). NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunol Res, 6(6), 636-644. (Read full article)
  42. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS (2018). Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest, 128(1), 531-544. (Read full article)
  43. Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ (2017). PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res, 77(21), e62-e66. (Read full article)
  44. Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL (2017). RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Sci Transl Med, 9(374). (Read full article)
  45. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, OConnor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C (2016). A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 167(1), 260-274.e22. (Read full article)
  46. Faham N, Welm AL (2016). RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harb Symp Quant Biol, 81, 177-188. (Read full article)
  47. Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL (2015). Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res, 21(24), 5588-600. (Read full article)
  48. Shen L, OShea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A, 112(17), 5425-30. (Read full article)
  49. Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC (2014). Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell, 25(18), 2695-709. (Read full article)
  50. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S (2014). Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res, 74(5), 1463-74. (Read full article)
  51. Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL (2014). The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep, 6(1), 141-54. (Read full article)
  52. Eyob H, Ekiz HA, Welm AL (2013). RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. Oncoimmunology, 2(9), e25670. (Read full article)
  53. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D (2013). Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis, 34(9), 2137-44. (Read full article)
  54. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL (2013). Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov, 3(7), 751-60. (Read full article)
  55. DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE (2013). Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol, Chapter 14, Unit14.23. (Read full article)
  56. Lum DH, Matsen C, Welm AL, Welm BE (2012). Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol, Chapter 14, Unit 14.22. (Read full article)
  57. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA (2012). Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell, 21(3), 430-46. (Read full article)
  58. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med, 17(11), 1514-20. (Read full article)
  59. Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS (2011). Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res, 71(16), 5579-87. (Read full article)
  60. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL (2011). Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer, 2(7), 753-62. (Read full article)
  61. Kretschmann KL, Eyob H, Buys SS, Welm AL (2010). The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets, 11(9), 1157-68. (Read full article)
  62. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL (2009). Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest, 119(9), 2663-77. (Read full article)
  63. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM (2009). Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res, 15(7), 2311-22. (Read full article)
  64. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM (2007). The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A, 104(18), 7570-5. (Read full article)

Review

  1. Blanchard Z, Brown EA, Ghazaryan A, Welm AL (2024). PDX models for functional precision oncology and discovery science. [Review]. Nat Rev Cancer. (Read full article)
  2. Stires H, Bado I, Brown T, Carlson M, Chan IS, Echeverria GV, Ewald AJ, Lim B, Lloyd C, Maues J, Oesterreich S, Riter RN, Shanahan K, Welm AL, Newby J (2022). Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. [Review]. NPJ Breast Cancer, 8(1), 75. (Read full article)
  3. Letai A, Bhola P, Welm AL (2021). Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. [Review]. Cancer Cell, 40(1), 26-35. (Read full article)
  4. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT (2016). Patient-derived xenograft (PDX) models in basic and translational breast cancer research. [Review]. Cancer Metastasis Rev, 35(4), 547-573. (Read full article)
  5. Kretschmann KL, Welm AL (2012). Mouse models of breast cancer metastasis to bone. [Review]. Cancer Metastasis Rev, 31(3-4), 579-83. (Read full article)

Case Report

  1. Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL (2022). A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer, 3(2), 232-250. (Read full article)

Other

  1. Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti R (2022). Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun (13(1), p. 3927). England. (Read full article)
  2. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L (2022). Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun (13(1), p. 294). England. (Read full article)
  3. Dai J, Cimino PJ, Gouin KH 3rd, Grzelak CA, Barrett A, Lim AR, Long A, Weaver S, Saldin LT, Uzamere A, Schulte V, Clegg N, Pisarsky L, Lyden D, Bissell MJ, Knott S, Welm AL, Bielas JH, Hansen KC, Winkler F, Holland EC, Ghajar CM (2021). Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Cancer (3(1), pp. 25-42). England. (Read full article)
  4. Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ (2021). Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res (81(24), pp. 6259-6272). United States. (Read full article)
  5. Scherer SD, Riggio AI, Haroun F, DeRose YS, Ekiz HA, Fujita M, Toner J, Zhao L, Li Z, Oesterreich S, Samatar AA, Welm AL (2021). An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Res (23(1), p. 100). England. (Read full article)
  6. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L (2021). Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun (12(1), p. 5086). England. (Read full article)
  7. Welm BE, Vaklavas C, Welm AL (2021). Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)]. APL Bioeng (5(2), p. 029901). United States. (Read full article)
  8. Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, OFarrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium (2021). Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet (53(5), p. 761). United States. (Read full article)
  9. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med (25(5), p. 861). United States. (Read full article)
  10. Welm AL (2003). AACR Special Conference: Advances in Breast Cancer Research--Genetics, Biology, and Clinical Implications, Huntington Beach, California, USA, 8-12 October 2003. Breast Cancer Res (6(1), pp. E6). England. (Read full article)

Patent

  1. (2018). Ron inhibitors as agents to prevent or treat bone loss. U.S. Patent No. US Patent #9,907,791. Washington, D.C.:U.S. Patent and Trademark Office.

News & Podcasts

Huntsman Cancer Institute News